These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15548845)

  • 1. Eisai hyperbilirubinemic rat (EHBR) as an animal model affording high drug-exposure in toxicity studies on organic anions.
    Naba H; Kuwayama C; Kakinuma C; Ohnishi S; Ogihara T
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):339-51. PubMed ID: 15548845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats.
    Naba H; Kakinuma C; Ohnishi S; Ogihara T
    Biochem Biophys Res Commun; 2006 Feb; 340(1):215-20. PubMed ID: 16364247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats.
    Chen C; Scott D; Hanson E; Franco J; Berryman E; Volberg M; Liu X
    Pharm Res; 2003 Jan; 20(1):31-7. PubMed ID: 12608533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats.
    Kuroda M; Kobayashi Y; Tanaka Y; Itani T; Mifuji R; Araki J; Kaito M; Adachi Y
    J Gastroenterol Hepatol; 2004 Feb; 19(2):146-53. PubMed ID: 14731123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats.
    Hirohashi T; Suzuki H; Ito K; Ogawa K; Kume K; Shimizu T; Sugiyama Y
    Mol Pharmacol; 1998 Jun; 53(6):1068-75. PubMed ID: 9614210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic analysis of ramatroban using a recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference in Sprague-Dawley and Eisai hyperbilirubinemic rats.
    Moriwaki T; Yasui H; Yamamoto A
    Pharm Res; 2004 Jun; 21(6):1055-64. PubMed ID: 15212172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats.
    Sathirakul K; Suzuki H; Yasuda K; Hanano M; Tagaya O; Horie T; Sugiyama Y
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1301-12. PubMed ID: 8510010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats.
    Gotoh Y; Suzuki H; Kinoshita S; Hirohashi T; Kato Y; Sugiyama Y
    J Pharmacol Exp Ther; 2000 Jan; 292(1):433-9. PubMed ID: 10604980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR- and EHBR rats.
    Newton DJ; Wang RW; Evans DC
    Life Sci; 2005 Jul; 77(10):1106-15. PubMed ID: 15913659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in glutathione homeostasis in mutant Eisai hyperbilirubinemic rats.
    Lu SC; Cai J; Kuhlenkamp J; Sun WM; Takikawa H; Takenaka O; Horie T; Yi J; Kaplowitz N
    Hepatology; 1996 Jul; 24(1):253-8. PubMed ID: 8707271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of biliary excretion of lithocholate-3-sulfate in Eisai hyperbilirubinemic rats (EHBR).
    Takikawa H; Nishikawa K; Sano N; Yamanaka M; Horie T
    Dig Dis Sci; 1995 Aug; 40(8):1792-7. PubMed ID: 7648982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Oatp and Mrp2 activities in hepatobiliary excretion using newly developed positron emission tomography tracer [11C]dehydropravastatin in rats.
    Shingaki T; Takashima T; Ijuin R; Zhang X; Onoue T; Katayama Y; Okauchi T; Hayashinaka E; Cui Y; Wada Y; Suzuki M; Maeda K; Kusuhara H; Sugiyama Y; Watanabe Y
    J Pharmacol Exp Ther; 2013 Oct; 347(1):193-202. PubMed ID: 23926287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethacrynic-acid-induced glutathione depletion and oxidative stress in normal and Mrp2-deficient rat liver.
    Ji B; Ito K; Sekine S; Tajima A; Horie T
    Free Radic Biol Med; 2004 Dec; 37(11):1718-29. PubMed ID: 15528031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of urinary excretion of pravastatin and temocapril in bile duct-ligated rats and Eisai hyperbilirubinemic rats (EHBR).
    Takada Y; Tachizawa H; Kurihara H; Takayanagi M; Sasamoto T; Akashi M; Aiso M; Takamori Y; Sano N; Takikawa H
    J Hepatobiliary Pancreat Surg; 2004; 11(2):125-8. PubMed ID: 15127276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR.
    Ito K; Suzuki H; Hirohashi T; Kume K; Shimizu T; Sugiyama Y
    Am J Physiol; 1997 Jan; 272(1 Pt 1):G16-22. PubMed ID: 9038871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver.
    Akita H; Suzuki H; Sugiyama Y
    Pharm Res; 2001 Aug; 18(8):1119-25. PubMed ID: 11587482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats.
    Takenaka O; Horie T; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1362-9. PubMed ID: 7562509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hyperbilirubinemia in Eisai hyperbilirubinemic rat by transfecting human MRP2/ABCC2 gene.
    Hirouchi M; Suzuki H; Sugiyama Y
    Pharm Res; 2005 Apr; 22(4):661-6. PubMed ID: 15846474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of rat multidrug resistance protein 2 in plasma and biliary disposition of dibromosulfophthalein after microsomal enzyme induction.
    Johnson DR; Klaassen CD
    Toxicol Appl Pharmacol; 2002 Apr; 180(1):56-63. PubMed ID: 11922777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan.
    Nishino A; Kato Y; Igarashi T; Sugiyama Y
    Drug Metab Dispos; 2000 Oct; 28(10):1146-8. PubMed ID: 10997931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.